Intracameral prostaglandin analogue therapy delivers durable
An extended-release intracameral implant loaded with travoprost (travoprost XR; ENV515, Envisia Therapeutics) was found to be well tolerated and effective for providing sustained IOP-lowering, according to 9-month interim analysis findings in an ongoing phase II trial.

The study included 5 patients with bilateral ocular hypertension or open-angle glaucoma previously treated with a topical prostaglandin analogue (PGA). They received a single dose of a low-dose formulation of the travoprost XR implant in one eye and used topical timolol maleate ophthalmic solution 0.5% contralaterally, twice daily.

The magnitude of the effect was comparable to that achieved prior to the study with topical prostaglandin treatment and during the study with topical timolol treatment in the fellow eye of the same patients.
Dr. F●●●●n K●●n and 2 other likes this